Immune Presentation and Regulation
Research Lines
Content with Investigacion .
Neisseria, Listeria y Bordetella
• Invasive Meningococcal Disease.
o Laboratory surveillance based on whole-genome sequencing and its application in Public Health.
o Study and characterization of antimicrobial resistance mechanisms.
o Study and evaluation of conventional (polysaccharide) and new-generation (protein) vaccines.
• Gonococcal Infection (Gonorrhea).
o Laboratory surveillance based on whole-genome sequencing and its application in Public Health.
o Study and characterization of antimicrobial resistance mechanisms.
• Listeriosis.
o Laboratory surveillance based on whole-genome sequencing and its application in Public Health.
• Pertussis.
o Development and application of molecular techniques for the diagnosis and characterization of Bordetella pertussis, B. parapertussis, B. holmessi, and B. bronchiseptica.
Research projects
Content with Investigacion .
1. Project Title: Determination of the degree of identity of common antigens of N. meningitidis and N. gonorrhoeae using genomic and immunological tools.
Principal Investigator: Raquel Abad Torreblanca
Funding Entity: ISCIII. Program: Strategic Action in Intramural Health
Reference: PI23CIII/00040
Period: 2024-2026
Amount Awarded: €68,500
2. Project Title: Meningococcal Disease and Molecular Epidemiology (MEMORY).
Principal Investigator: Raquel Abad Torreblanca and Julio A. Vázquez Moreno
Funding Entity: Pfizer Inc.
Reference: MVP 352/21
Period: 2022-2024
Amount Awarded: €82,834.50
3. Project Title: Modelling Approaches to Guide Intelligent Surveillance for the Sustainable Introduction of Novel Antibiotics. MAGIcIAN.
Principal Investigator: Raquel Abad Torreblanca
Funding Entity: ISCIII / International Joint Action / Joint Programming Initiatives (JPI) Program
Reference: AC19CIII/00002
Period: 2020-2024
Amount Awarded: €46,000
4. Project Title: Epidemiological, Microbiological, and Clinical Analysis of the Listeriosis Outbreak in Andalusia. LISMOAN Study.
Principal Investigator: José Miguel Cisneros Herreros
Funding Entity: FISEVI (Andalusian Public Foundation for Health Research Management)/FPS2020 Call for Proposals
Reference: PI-0001-2020
Period: 2020-2023
Amount Awarded: €114,954
5. Project Title: Population Structure of Neisseria meningitidis Using Massive Sequencing: A Potential Tool for Estimating Vaccine Effectiveness?
Principal Investigator: Raquel Abad Torreblanca
Funding Entity: ISCIII / Strategic Action in Intramural Health
Reference: PI19CIII/00030
Period: 2020-2023
Amount Awarded: €67,153
6. Project Title: Management agreement between the Ministry of Health, Social Services and Equality (Directorate General of Public Health, Quality and Innovation) and the Carlos III Health Institute, for the laboratory determinations corresponding to the 2nd seroprevalence study in Spain.
Principal Investigator: Fernando de Ory and Julio A. Vázquez
Funding Entity: Directorate General of Public Health, Ministry of Health
Reference: MEG151/17
Period: 2018-2020
Amount Awarded: €565,663
7. Project Title: Effectiveness of the Meningococcal B Vaccine in Immunocompromised Children with Sickle Cell Disease
Principal Investigator: Raquel Abad Torreblanca
Funding Entity: Spanish Society of Pediatric Hematology and Oncology Foundation (SEHOP)
Reference: MVP 199/18
Period: 2018-2020
Amount Awarded: €18,285
8. Project Title: Application of Massive Sequencing and Immunological Approaches in the Expression Analysis of New Vaccine Antigens in Meningococcal Populations
Principal Investigator: Raquel Abad Torreblanca
Funding Entity: ISCIII / Strategic Action in Intramural Health
Reference: PI16CIII/00023
Period: 2017-2020
Amount Awarded: €115,084
9. Project Title: fHbp variability over time and potential coverage of the new meningococcal serogroup B vaccine (bivalent rLP2086/fHbp) in Spain.
Principal Investigators: Raquel Abad and Julio A. Vázquez
Funding Entity: Pfizer SLU
Reference: MVP 1273/16
Period: 2017-2020
Amount Awarded: €125,350
10. Project Title: Estimation of protection of a conjugate vaccine against meningococcus serogroup C based on a mathematical model.
Principal Investigator: Julio A. Vázquez and Javier Díez
Funding Entity: Higher Center for Research in Public Health (CSISP)
Reference: MVP 1116/11
Period: 2011-2017
Amount awarded: €143,750
Publications
DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance
9. Conde P, Rodriguez M, van der Touw W, Jimenez A, Burns M, Miller J, Brahmachary M, Chen HM, Boros P, Rausell-Palamos F, Yun TJ, Riquelme P, Rastrojo A, Aguado B, Stein-Streilein J, Tanaka M, Zhou L, Zhang J, Lowary TL, Ginhoux F, Park CG, Cheong C, Brody J, Turley SJ, Lira SA, Bronte V, Gordon S, Heeger PS, Merad M, Hutchinson J, Chen SH, Ochando J. 2015. DC-SIGN(+) Macrophages Control the Induction of Transplantation Tolerance. Immunity. 16;42(6):1143-58.
PUBMED DOIProteomic characterisation of bovine and avian purified protein derivatives and identification of specific antigens for serodiagnosis of bovine tuberculosis
2.- Proteomic characterisation of bovine and avian purified protein derivatives and identification of specific antigens for serodiagnosis of bovine tuberculosis. Antonio Infantes-Lorenzo, Jose; Moreno, Inmaculada; Angeles Risalde, Maria; et ál. CLINICAL PROTEOMICS Volumen: 14 Número de artículo: 36 Fecha de publicación: NOV 2 2017
PUBMED DOIFunctional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.
3.- Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications. Subias Hidalgo, Marta; Yebenes, Hugo; Rodriguez-Gallego, Cesar; et ál..EUROPEAN JOURNAL OF IMMUNOLOGY Volumen: 47 Número: 3 Páginas: 504-515 Fecha de publicación: MAR 2017
PUBMED DOIImmunoproteomic characterisation of Mycoplasma mycoides subspecies capri by mass spectrometry analysis of two- dimensional electrophoresis spots and western blot
5.- Immunoproteomic characterisation of Mycoplasma mycoides subspecies capri by mass spectrometry analysis of two- dimensional electrophoresis spots and western blot. Churchward, Colin P.; Rosales, Ruben S.; Gielbert, Adriana; et ál..JOURNAL OF PHARMACY AND PHARMACOLOGY Volumen: 67 Número: 3 Número especial: SI Páginas: 364-371 Fecha de publicación: MAR 2015
PUBMED DOIEfficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
6.- Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis. Corral, M. Jesus; Serrano, Dolores R.; Moreno, Inmaculada; et ál..JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY Volumen: 69 Número: 12 Páginas: 3268-3274 Fecha de publicación: DEC 2014
PUBMED DOIAdditional Information
The group is interested in the study of the immune response from a multidisciplinary perspective that includes genomic, biochemical, proteomic, in vivo and biotechnological models aimed at the design of therapeutic strategies against various chronic, infectious and rare diseases that have a clear immunological component in their etiology.
The current specific objectives focus on:
- Antigenic presentation: Identification of antigenic presentation rules for their application in the design of therapeutic treatments including vaccines.
- Study of CD69 function and its regulation; its use as a therapeutic target in the mobilization of hematopoietic precursors and in the potentiation of the immune response mediated by CD69 with the potentiation of vaccines using the vaccinia virus as a vector.
The group is interested in the study of the immune response from a multidisciplinary perspective that includes genomic, biochemical, proteomic, in vivo and biotechnological models aimed at the design of therapeutic strategies against various chronic, infectious and rare diseases that have a clear immunological component in their etiology.
The current specific objectives focus on:
- Antigenic presentation: Identification of antigenic presentation rules for their application in the design of therapeutic treatments including vaccines.
- Study of CD69 function and its regulation; its use as a therapeutic target in the mobilization of hematopoietic precursors and in the potentiation of the immune response mediated by CD69 with the potentiation of vaccines using the vaccinia virus as a vector.
